Funder: Pfizer Inc.
Due Dates: April 9, 2026 (Submission Deadline — full proposal, 23:59 EST)
Funding Amounts: Up to EUR 40,000 per project; total available budget EUR 140,000; project length up to 18 months
Summary: Funds quality improvement projects to enhance non-pharmacological management and quality of life for ALK-positive lung cancer patients treated with ALK TKIs in Spain.
Key Information: Only organizations (not individuals) based in Spain may apply; applications after deadline will not be reviewed.